Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Astellas acquired Audentes Therapeutics for ~$3B for gene therapy.
Astellas to acquire gene therapy firm Audentes for $3 billion, adding a fifth Primary Focus Area in Genetic Regulation and positioning itself as a global…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Astellas acquired Audentes Therapeutics for ~$3B for gene therapy.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Astellas Pharma Inc. / Audentes Therapeutics (this deal) | 2019 | $3.0B | 23 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Astellas Pharma Inc. / Ganymed Pharmaceuticals | 2016 | $1.4B | 81 |
| Astellas Pharma Inc. / Sangamo Therapeutics, Inc. | 2026 | $50M | 63 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
| Astellas Pharma Inc. / Ocata Therapeutics, Inc. | 2015 | $379M | 41 |
| Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc. | 2012 | $90M | 38 |
← Browse all deals · How we score deals
More: 2019 deals · Astellas Pharma Inc. deals · Gene Therapy deals